To include your compound in the COVID-19 Resource Center, submit it here.

J&J ends deal for Macrogenics' duvortuxizumab

MacroGenics Inc. (NASDAQ:MGNX) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) terminated its license to duvortuxizumab (MGD011), a bispecific

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE